The risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Mianserin. The therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Mianserin. The serum concentration of Thioridazine can be increased when it is combined with Mianserin. Mianserin may increase the anticholinergic activities of Propantheline. The therapeutic efficacy of Clonidine can be decreased when used in combination with Mianserin. Mianserin may increase the anticholinergic activities of Mecamylamine. Mianserin may increase the anticholinergic activities of Darifenacin. The metabolism of Mianserin can be decreased when combined with Artemether. The therapeutic efficacy of Methamphetamine can be decreased when used in combination with Mianserin. The therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Mianserin. The risk or severity of adverse effects can be increased when Procarbazine is combined with Mianserin. The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mianserin. The risk or severity of adverse effects can be increased when Iproniazid is combined with Mianserin. Mianserin may increase the anticholinergic activities of Homatropine. The metabolism of Mianserin can be decreased when combined with Nicardipine. The metabolism of Mianserin can be decreased when combined with Methadone. The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Mianserin. The therapeutic efficacy of Paliperidone can be decreased when used in combination with Mianserin. The metabolism of Mianserin can be decreased when combined with Venlafaxine. The metabolism of Mianserin can be decreased when combined with Paroxetine. The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Mianserin. The metabolism of Mianserin can be decreased when combined with Clomipramine. Ritobegron may decrease the sedative activities of Mianserin. The therapeutic efficacy of Guanabenz can be decreased when used in combination with Mianserin. The risk or severity of adverse effects can be increased when Furazolidone is combined with Mianserin. Mianserin may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital. The metabolism of Mianserin can be decreased when combined with Saquinavir. The therapeutic efficacy of Etiracetam can be decreased when used in combination with Mianserin. The serum concentration of Mianserin can be increased when it is combined with Dasatinib. The serum concentration of Mianserin can be increased when it is combined with Aprepitant. Mianserin may increase the anticholinergic activities of Aclidinium. The serum concentration of Mianserin can be increased when it is combined with Ivacaftor. The metabolism of Mianserin can be decreased when combined with Sertraline. The serum concentration of Mianserin can be increased when it is combined with Ceritinib. Mianserin may increase the anticholinergic activities of Oxitropium. Mianserin may increase the anticholinergic activities of Tubocurarine. Mianserin may increase the anticholinergic activities of Gallamine Triethiodide. The metabolism of Mianserin can be decreased when combined with Ziprasidone. The therapeutic efficacy of Estazolam can be decreased when used in combination with Mianserin. 3,4-Methylenedioxyamphetamine may decrease the sedative activities of Mianserin. Mianserin may increase the anticholinergic activities of Vecuronium. The therapeutic efficacy of Pergolide can be decreased when used in combination with Mianserin. The metabolism of Mianserin can be decreased when combined with Chlorpromazine. The therapeutic efficacy of Bethanidine can be decreased when used in combination with Mianserin. The risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Mianserin. Mianserin may increase the anticholinergic activities of Methylscopolamine bromide. The serum concentration of Mianserin can be decreased when it is combined with Lumacaftor. The metabolism of Mianserin can be decreased when combined with Isoniazid. The serum concentration of Mianserin can be increased when it is combined with Stiripentol. The metabolism of Mianserin can be decreased when combined with Posaconazole. The metabolism of Mianserin can be decreased when combined with Isavuconazonium. Mianserin may increase the anticholinergic activities of Scopolamine. The therapeutic efficacy of Phenobarbital can be decreased when used in combination with Mianserin. Dextroamphetamine may decrease the sedative activities of Mianserin. The serum concentration of Mianserin can be increased when it is combined with Fusidic Acid. The metabolism of Mianserin can be decreased when combined with Atomoxetine. The serum concentration of Mianserin can be increased when it is combined with Osimertinib. The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Mianserin. The risk or severity of adverse effects can be increased when Iproclozide is combined with Mianserin. Mianserin may increase the anticholinergic activities of Oxyphenonium. Mephedrone may decrease the sedative activities of Mianserin. The therapeutic efficacy of Primidone can be decreased when used in combination with Mianserin. The therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Mianserin. The risk or severity of adverse effects can be increased when Octamoxin is combined with Mianserin. The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Mianserin. Mianserin may increase the anticholinergic activities of Pancuronium. The therapeutic efficacy of Acetazolamide can be decreased when used in combination with Mianserin. The metabolism of Mianserin can be decreased when combined with Betaxolol. The metabolism of Mianserin can be decreased when combined with Clozapine. The therapeutic efficacy of Ephedra can be decreased when used in combination with Mianserin. The therapeutic efficacy of Riluzole can be decreased when used in combination with Mianserin. Mephentermine may decrease the sedative activities of Mianserin. The therapeutic efficacy of Diazepam can be decreased when used in combination with Mianserin. The therapeutic efficacy of Mephenytoin can be decreased when used in combination with Mianserin. The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mianserin. Mianserin may increase the anticholinergic activities of Trihexyphenidyl. The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Mianserin. Mianserin may increase the central nervous system depressant (CNS depressant) activities of Barbital. The therapeutic efficacy of Guanfacine can be decreased when used in combination with Mianserin. The therapeutic efficacy of Droxidopa can be decreased when used in combination with Mianserin. The metabolism of Mianserin can be decreased when combined with Atazanavir. 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Mianserin. Mianserin may increase the anticholinergic activities of Orphenadrine. The metabolism of Mianserin can be decreased when combined with Thiotepa. Mianserin may increase the anticholinergic activities of Tropicamide. The metabolism of Mianserin can be decreased when combined with Rolapitant. The serum concentration of Mianserin can be increased when it is combined with Cobicistat. The metabolism of Mianserin can be decreased when combined with Lovastatin. The metabolism of Mianserin can be decreased when combined with Lumefantrine. The metabolism of Mianserin can be decreased when combined with Mexiletine. The metabolism of Mianserin can be decreased when combined with Lopinavir. The therapeutic efficacy of Zonisamide can be decreased when used in combination with Mianserin. The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Mianserin. Chlorphentermine may decrease the sedative activities of Mianserin. The therapeutic efficacy of Apraclonidine can be decreased when used in combination with Mianserin. Lisdexamfetamine may decrease the sedative activities of Mianserin. The therapeutic efficacy of Lorazepam can be decreased when used in combination with Mianserin. The therapeutic efficacy of Naphazoline can be decreased when used in combination with Mianserin. Mianserin may increase the anticholinergic activities of Ethopropazine. The metabolism of Mianserin can be decreased when combined with Rucaparib. Mianserin may increase the anticholinergic activities of Benzatropine. The metabolism of Mianserin can be decreased when combined with Fluconazole. The therapeutic efficacy of Trimethadione can be decreased when used in combination with Mianserin. The metabolism of Mianserin can be decreased when combined with Cholecalciferol. The metabolism of Mianserin can be decreased when combined with Desipramine. The therapeutic efficacy of Tizanidine can be decreased when used in combination with Mianserin. The metabolism of Mianserin can be decreased when combined with Chloroquine. The therapeutic efficacy of Eperisone can be decreased when used in combination with Mianserin. The risk or severity of adverse effects can be increased when Hydracarbazine is combined with Mianserin. The metabolism of Mianserin can be decreased when combined with Cocaine. Mianserin may increase the anticholinergic activities of Dexetimide. The risk or severity of adverse effects can be increased when Phenelzine is combined with Mianserin. The therapeutic efficacy of Vinpocetine can be decreased when used in combination with Mianserin. The metabolism of Mianserin can be decreased when combined with Clopidogrel. Mianserin may increase the anticholinergic activities of Glycopyrronium. The therapeutic efficacy of MK-212 can be decreased when used in combination with Mianserin. Mianserin may increase the anticholinergic activities of Chlorphenoxamine. Mianserin may increase the anticholinergic activities of Pipecuronium. The risk or severity of adverse effects can be increased when Pargyline is combined with Mianserin. The metabolism of Mianserin can be decreased when combined with Azithromycin. The metabolism of Mianserin can be increased when combined with Nevirapine. The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mianserin. Mianserin may increase the central nervous system depressant (CNS depressant) activities of Secobarbital. Mianserin may increase the anticholinergic activities of Oxybutynin. The risk or severity of adverse effects can be increased when Pirlindole is combined with Mianserin. The risk or severity of adverse effects can be increased when Benmoxin is combined with Mianserin. The metabolism of Mianserin can be decreased when combined with Clemastine. The metabolism of Mianserin can be decreased when combined with Doxorubicin. The therapeutic efficacy of Topiramate can be decreased when used in combination with Mianserin. The therapeutic efficacy of Metharbital can be decreased when used in combination with Mianserin.